title: Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines.
abstract: Six pentavalent pneumococcal conjugate vaccines (Pn-CRM197) were evaluated among 400 infants. The vaccines differed in saccharide chain length (oligosaccharide [OS] or polysaccharide [PS]) and saccharide quantity (0.5, 2, or 5 microg). Subjects were randomized into groups 1-6 (Pn-CRM197 recipients) or 7 (controls) for immunization at 2, 4, and 6 months of age. Pn-CRM197 were well tolerated and elicited mean antibody concentrations that exceeded those in controls for all 5 capsular serotypes. PS formulations were generally more immunogenic than their OS counterparts. For PS vaccines, a dose-response was documented (5 microg > 2 microg > 0.5 microg), but the differences between the 5- and 2-microg formulations were insignificant. The mean anti-PRP antibody concentration was significantly higher among Pn-CRM197 recipients. It is concluded that PS vaccines are more immunogenic than OS vaccines. The improved immunogenicity from Haemophilus type b oligosaccharide conjugate (HbOC) vaccine when given with Pn-CRM197 suggests that a decreased dose of HbOC vaccine may be sufficient to elicit protection.
authors.affiliation: Department of Pediatrics, University of Chicago, Illinois, USA.
authors.forename: R S
authors.initials: RS
authors.lastname: Daum
authors.forename: D
authors.initials: D
authors.lastname: Hogerman
authors.forename: M B
authors.initials: MB
authors.lastname: Rennels
authors.forename: K
authors.initials: K
authors.lastname: Bewley
authors.forename: F
authors.initials: F
authors.lastname: Malinoski
authors.forename: E
authors.initials: E
authors.lastname: Rothstein
authors.forename: K
authors.initials: K
authors.lastname: Reisinger
authors.forename: S
authors.initials: S
authors.lastname: Block
authors.forename: H
authors.initials: H
authors.lastname: Keyserling
authors.forename: M
authors.initials: M
authors.lastname: Steinhoff
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood*; D016667:Bacterial Capsules / Q000276:immunology; D001426:Bacterial Proteins / Q000276:immunology*; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000276:immunology*; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000276:immunology; D018073:Haemophilus Vaccines / Q000276:immunology*; D006801:Humans; D007223:Infant; D009844:Oligosaccharides / Q000276:immunology*; D011008:Pneumococcal Infections / Q000517:prevention & control; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D013296:Streptococcus pneumoniae / Q000276:immunology*; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000009:adverse effects / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; D009844:Oligosaccharides; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate; C028581:CRM197 (non-toxic variant of diphtheria toxin); C061963:HibTITER protein, Haemophilus influenzae